Targeting of identified HDAC, ATM, and p38 pathways shows radiosensitizing potential in cancer cells, and the clinically approved HDAC inhibitor vorinostat (SAHA) significantly improves the efficacy of TAT in vivo. The gene discussed is HDAC9; the disease is cancer.